sinc
refin
tissu
cultur
techniqu
viru
isol
propag
mid
onward
veterinari
virolog
receiv
much
academ
industri
interest
becom
major
global
industri
larg
centr
vaccin
develop
econom
import
viru
diseas
food
anim
biotech
approach
wide
use
improv
vaccin
develop
mani
viral
diseas
control
vaccin
mani
still
lack
safe
efficaci
vaccin
addit
challeng
face
academia
industri
govern
like
come
virus
jump
speci
also
emerg
virul
variant
establish
virus
due
natur
mutat
also
viral
ecolog
chang
respect
vector
adapt
new
habitat
shown
recent
incurs
bluetongu
viru
europ
paper
current
vaccin
livestock
hors
bird
describ
speci
speci
order
new
promis
biotech
approach
use
revers
genet
nonrepl
viral
vector
alpha
viru
vector
genet
vaccin
conjunct
better
adjuv
better
way
vaccin
deliveri
discuss
well
marek
first
pioneer
demonstr
principl
vaccin
control
highli
pathogen
infect
smallpox
human
turn
centuri
english
doctor
edward
jenner
use
rumin
counterpart
small
pox
cowpox
viru
sinc
earli
vaccin
principl
appli
control
diseas
caus
member
mani
viru
famili
affect
human
anim
much
benefit
although
mani
viral
diseas
product
anim
truli
global
virus
present
found
part
world
virus
may
howev
spread
geograph
region
andor
broaden
host
rang
case
bluetongu
viru
west
nile
viru
wnv
global
viral
diseas
vaccin
mani
region
viral
diseas
immunoprophylaxi
control
respect
noteworthi
exampl
newli
emerg
paramyxovirus
genu
nipah
viru
goal
vaccin
induc
immun
particular
speci
prevent
clinic
diseas
excret
infect
pathogen
microorgan
sinc
first
smallpox
vaccin
jenner
numer
differ
approach
vaccin
develop
tradit
vaccin
formul
divid
two
major
class
live
inactiv
tabl
live
vaccin
contain
attenu
nonpathogen
strain
pathogen
express
vector
vaccin
unabl
induc
diseas
abl
induc
suitabl
immun
overattenu
potenti
risk
vaccin
scientist
awar
challeng
vaccin
develop
find
right
balanc
virul
vaccin
viru
abil
replic
suffici
order
induc
immun
attenu
achiev
mani
differ
way
exampl
given
tabl
approach
use
passag
pathogen
cell
cultur
deriv
andor
isol
temperatur
sensit
mutant
restrict
signific
replic
intern
bodi
organ
use
relat
apathogen
strain
jenner
yet
anoth
exampl
modern
methodolog
would
involv
use
molecular
biolog
techniqu
remov
virul
gene
pathogen
engin
nonpathogen
replic
agent
express
immun
induc
antigen
epitop
pathogen
replicationdefect
vector
also
develop
safe
effect
vaccin
viral
diseas
live
vaccin
gener
induc
immun
respons
use
situat
antibodi
respons
correl
protect
exist
circul
antibodi
interfer
induct
immunolog
respons
interfer
due
matern
deriv
antibodi
mda
unwean
host
common
problem
particularli
kill
vaccin
administ
parenter
mani
viral
diseas
kill
inactiv
vaccin
wide
use
safe
option
kill
vaccin
gener
induc
humor
immun
respons
often
requir
use
adjuv
boost
immun
respons
adjuv
play
major
role
direct
immun
respons
aluminium
hydroxid
instanc
strong
induc
humor
immun
respons
wherea
other
saponin
deriv
may
induc
cellular
respons
well
refer
therein
case
live
vaccin
differ
inactiv
vaccin
formul
known
inactiv
whole
viru
vaccin
subunit
vaccin
peptid
vaccin
split
virion
vaccin
overview
look
exist
vaccin
current
approach
toward
develop
new
prospect
vaccin
livestock
hors
bird
stage
relev
refer
regulatori
legisl
control
viral
diseas
livestock
european
union
vaccin
develop
process
industri
perspect
import
point
respect
essenti
perform
data
frequent
limit
compani
registr
dossier
littl
inform
safeti
efficaci
therefor
public
domain
mani
diseas
valid
challeng
model
assess
efficaci
nonexist
moreov
vaccin
efficaci
data
often
come
field
trial
notwithstand
drawback
articl
view
shortcom
vaccin
offer
idea
improv
propos
five
herp
virus
natur
infect
hors
two
alpha
virus
equin
import
occur
worldwid
caus
febril
respiratori
diseas
type
hors
addit
associ
abort
andor
paresi
lateterm
transplacent
infect
neonat
foal
diseas
biolog
control
infect
recent
review
vaccin
virus
common
use
least
multival
mostli
kill
vaccin
use
tissu
cultur
grown
mani
also
contain
egggrown
equin
influenza
virus
product
howev
claim
protect
respiratori
diseas
due
none
protect
foal
mda
consid
import
epidemiolog
transmiss
virus
see
two
vaccin
one
eu
one
usa
see
claim
protect
abort
three
parenter
vaccin
month
gestat
vaccin
found
offer
limit
protect
field
condit
gener
accept
vaccin
improv
efficaci
particularli
abil
protect
abort
paresi
infect
passiv
immun
unwean
foal
prevent
spread
infect
requir
howev
much
effort
toward
goal
deriv
delet
mutant
live
vaccin
similar
line
alpha
herp
virus
notabl
pseudorabi
viru
prv
bovin
disappoint
experiment
live
temperatur
sensit
ts
vaccin
shown
remark
efficaci
abort
paresi
challeng
pregnant
mare
month
singl
intranas
vaccin
experiment
vaccin
also
crossprotect
yearl
febril
respiratori
diseas
viru
shed
also
significantli
protect
foal
mda
upon
challeng
three
import
consider
epidemiolog
control
equin
influenza
virus
eiv
infect
given
popul
hors
need
fulli
vaccin
prevent
epidem
influenza
crossprotect
antibodi
subtyp
eiv
incid
eiv
infect
countri
hors
breed
race
industri
major
commerci
avail
eiv
vaccin
egggrown
eiv
subtyp
either
kill
whole
viru
eiv
surfac
glycoprotein
subunit
vaccin
contain
differ
adjuv
vaccin
howev
induc
poor
cytotox
lymphocyt
ctl
respons
protect
usual
shortliv
associ
titr
antibodi
viru
haemagglutinin
ha
qualiti
eiv
vaccin
vari
kill
whole
viru
vaccin
found
protect
hors
least
year
three
vaccin
month
age
import
observ
induct
toler
kill
vaccin
hors
mda
known
long
time
much
durabl
respons
humor
cellular
immun
confer
protect
occur
follow
eiv
infect
thu
live
attenu
eiv
vaccin
mimick
natur
infect
afford
far
superior
protect
kill
vaccin
howev
realiti
one
live
attenu
ts
coldadapt
strain
vaccin
come
market
usa
nowher
els
yet
eu
eiv
offer
two
separ
canari
poxviru
recombin
express
ha
eiv
european
american
lineag
vaccin
formul
carbom
adjuv
shown
induc
humor
cellular
immun
respons
iscomatrix
adjuv
vaccin
induc
cellular
immun
respons
variou
anim
model
well
although
evidenc
hors
yet
optim
vaccin
schedul
equin
influenza
current
evalu
vaccin
offer
best
protect
upon
tradit
vaccin
schedul
wherea
other
american
hors
endhost
three
distinct
serotyp
alpha
viru
known
equin
encephalomyel
viru
eev
geograph
defin
eastern
usa
eeev
western
usa
weev
venezuelan
veev
serotyp
three
serotyp
carri
healthi
small
rodent
bird
transmit
mosquito
bite
viru
carri
saliva
insect
bite
result
viraemia
viscer
viral
replic
accompani
fever
depress
anorexia
death
veev
replic
usual
confin
viscera
mortal
weev
eeev
viscer
viru
replic
also
localis
central
nervou
system
cn
result
mortal
respect
immunoprophylaxi
virus
kill
adjuv
vaccin
also
contain
wnv
instanc
innov
ewt
fort
dodg
anim
health
contain
wnv
eeev
weev
tetanu
toxoid
hors
endhost
wnv
preval
countri
mosquito
thrive
notabl
part
africa
middl
east
central
north
america
canada
becam
endem
last
decad
wnv
epidemiolog
pathogenesi
similar
eev
three
wnv
vaccin
current
market
use
hors
wnv
like
eev
caus
signific
diseas
anim
speci
includ
man
current
wnv
vaccin
trival
wnv
eeev
tetanu
product
canari
poxviru
vector
live
vaccin
chimer
wnv
glycoproteinyellow
fever
viru
backbon
vaccin
also
licens
human
immunis
african
hors
sick
ah
highli
fatal
insect
culicoid
spp
transmit
diseas
equida
hors
mule
donkey
zebra
caus
ah
viru
ahsv
genu
orbiviru
famili
reovirida
ahsv
pantrop
pneumon
viscer
replic
endem
part
africa
sporad
cross
southern
europ
part
middl
east
annual
vaccin
polyval
multiserotyp
mousebrain
tissu
cultur
grown
live
viru
vaccin
futur
vaccin
may
use
ahsv
surfac
protein
subunit
biotech
vaccin
plasmid
dna
vaccin
pathogenesi
epidemiolog
ah
similar
infect
rumin
anoth
import
veterinari
orbiviru
name
bluetongu
viru
see
sheep
virus
virus
bite
midg
speci
culicoid
imicola
other
import
transmiss
although
ah
import
diseas
equida
economi
warrant
vaccin
develop
us
eu
market
equin
arter
viru
eav
occur
mainli
usa
northern
europ
caus
haemorrhag
necrot
lesion
medium
size
blood
vessel
oedema
diarrhoea
colic
abort
tissu
cultur
attenu
live
viru
vaccin
protect
contraind
use
late
pregnant
mare
safer
option
live
intranas
vaccin
might
deriv
temperatur
sensit
mutant
similar
line
appli
abort
isol
equin
infecti
anaemia
viru
eiav
widespread
damp
area
usa
japan
part
europ
hors
eiav
caus
haemolyt
anaemia
jaundic
haemorrhag
inflamm
spleen
liver
kidney
fever
gener
lentiviru
vaccin
difficult
develop
evidenc
absenc
good
vaccin
hiv
fiv
felv
howev
live
attenu
eiav
vaccin
develop
china
widespread
use
sinc
anoth
live
eiav
vaccin
develop
usa
eu
eiav
vaccin
avail
cattl
wide
market
vaccin
compris
virus
bacteria
implic
bovin
respiratori
diseas
complex
brdc
major
caus
econom
loss
cattl
industri
global
apart
mannheimia
spp
virus
main
agent
involv
particular
parainfluenza
type
viru
bovin
respiratori
syncyti
viru
brsv
bovin
viral
diarrhoea
viru
bvdv
virus
combin
vaccin
avail
brdc
vaccin
present
offer
eu
america
vari
respect
valenc
vaccin
constitut
thu
america
brdc
vaccin
tend
polyval
cocktail
viral
bacteri
pathogen
live
kill
prepar
wherea
eu
bvdv
abort
vaccin
variou
manufactur
larg
offer
monoval
product
market
combin
andor
brsv
mannheimia
intervet
bovipast
instanc
vaccin
composit
brsv
pasteurella
success
use
mani
year
grow
interest
market
live
kill
glycoprotein
e
defici
ge
vaccin
view
use
marker
diva
see
vaccin
erad
campaign
recent
studi
shown
inactiv
bvdv
vaccin
properti
marker
vaccin
antibodi
viral
nonstructur
protein
produc
occur
low
concentr
vaccin
anim
latter
would
howev
negat
marker
vaccin
claim
sinc
definit
distinct
vaccin
field
infect
cattl
would
possibl
also
efficaci
regist
vaccin
respiratori
diseas
name
infecti
bovin
rhinotrach
ibr
genit
lesion
import
awar
vaccin
complet
prevent
viru
shed
respiratori
tract
bvdv
major
caus
reproduct
loss
cattl
industri
transplacent
foetal
infect
america
bvdv
vaccin
abort
claim
rare
eu
bvdv
abort
vaccin
consid
import
current
avail
torvacbvd
novarti
anim
health
bovili
bvdv
intervet
intern
preg
sure
bvd
pfizer
anim
health
interest
observ
compar
three
bvdv
abort
claim
studi
method
assess
incid
transplacent
infect
due
bvdv
challeng
one
studi
anim
kill
fix
time
follow
challeng
pregnanc
rate
assess
two
abort
efficaci
studi
allow
ongo
pregnanc
go
term
natur
bvdv
posit
foetus
newli
born
calv
assess
bvdv
infect
bvdv
challeng
method
also
differ
natur
challeng
persist
bvdv
infect
calv
perform
one
studi
wherea
bvdv
challeng
administ
inocul
two
studi
natur
challeng
infect
anim
quickli
interestingli
measur
challeng
administ
inocul
uniformli
infecti
foetu
indic
challeng
potent
current
avail
vaccin
complet
prevent
viru
shed
febril
respiratori
diseas
differ
potenc
futur
brdc
vaccin
includ
type
bvdv
strain
control
abort
besid
main
claim
prevent
respiratori
diseas
control
brdc
better
protect
brsv
desir
approach
investig
live
delet
mutant
lack
g
sh
andor
gene
deriv
use
revers
genet
techniqu
well
isol
coldadapt
produc
ts
strain
problem
live
brsv
vaccin
wild
type
viru
strain
grow
poorli
tissu
cultur
good
consist
growth
critic
requir
vaccin
manufactur
good
growth
even
less
like
delet
mutant
brsv
strain
interest
approach
overcom
poor
inconsist
yield
brsv
antigen
deriv
persist
infect
brsv
bovin
cell
line
cell
cell
line
viabl
express
brsv
antigen
upon
routin
subcultur
handicap
brsv
efficaci
studi
lack
reliabl
pathogen
challeng
model
brsv
cattl
particularli
unwean
calv
matern
antibodi
also
problem
compon
brdc
number
new
vaccin
idea
bvdv
includ
select
live
attenu
strain
use
biotech
techniqu
identifi
virulenceassoci
gene
remov
express
viru
glycoprotein
vector
nonrepl
nrvvsee
replic
subunit
vaccin
produc
varieti
express
vector
use
new
mucos
adjuv
multicompon
liposom
one
attract
propos
develop
edibl
vaccin
transgen
clover
exampl
howev
question
whether
approach
feasibl
regulatori
econom
perspect
classic
vector
virusbas
somewhat
unorthodox
approach
taken
recent
bvdv
vaccin
worker
assess
efficaci
recombin
viru
express
bvdv
type
structur
protein
c
e
rn
simment
calv
vaccin
intramuscularli
im
twice
week
apart
challeng
bvdv
type
strain
unusu
approach
gave
disappoint
result
protect
viraemia
leucopoenia
nasal
shed
partial
along
poor
viru
neutralis
antibodi
respons
direct
vector
approach
express
bvdv
type
glycoprotein
best
knowledg
recombin
test
efficaci
current
control
bovin
diarrhoea
immunis
pregnant
cattl
elev
milk
antibodi
titr
enter
virus
bacteria
three
kill
polyval
rota
viru
corona
viru
escherichia
coli
antigen
vaccin
one
live
virus
kill
e
coli
present
market
gener
critic
current
brdc
vaccin
current
licens
vaccin
assess
use
differ
challeng
model
challeng
viru
strain
anim
differ
age
background
dose
strain
challeng
viru
inocula
paramount
unifi
valid
challeng
method
establish
use
vaccin
compani
addit
valid
laboratori
test
reagent
european
union
stop
routin
vaccin
footandmouth
diseas
viru
fmdv
end
control
sporad
outbreak
fmd
within
eu
slaughter
movement
control
stamp
disinfect
infect
area
eu
legisl
forese
need
emerg
vaccin
eventu
eu
fmdv
antigen
bank
seven
serotyp
polici
ring
vaccin
cull
contribut
fmd
control
netherland
outbreak
howev
develop
serolog
test
discrimin
vaccin
infect
anim
consid
desir
emerg
vaccin
socal
diva
principl
see
endem
area
kill
whole
viru
vaccin
differ
adjuv
singl
multiserotyp
formul
use
larg
quantiti
import
highlight
difficulti
immunoprophylaxi
fmd
lack
crossreact
seven
serotyp
viru
strain
variat
serotyp
pose
major
difficulti
diagnosi
control
compound
continu
circul
endem
region
viru
high
mutat
rate
per
nucleotid
site
per
genom
replic
add
difficulti
vaccinebas
control
diseas
face
increas
globalis
current
fmd
vaccin
produc
grow
live
viru
cell
roller
bottl
suspens
biosecur
condit
larg
volum
antigen
inactiv
blend
adjuv
current
kill
fmdv
vaccin
effect
term
clinic
protect
give
steril
immun
also
elicit
quick
onset
long
last
immun
gener
onset
immun
week
primari
vaccin
difficulti
asid
much
effort
base
viral
vector
sendai
viru
replicationdefect
adenoviru
capri
pox
viru
vaccinia
viru
express
vn
epitop
fmdv
protein
andor
peptid
thereof
cell
epitop
viral
nonstructur
protein
select
cytokin
gene
adenovirusfmdv
andor
cytokin
recombin
promis
vaccin
candid
respect
quicker
onset
longer
durat
immun
well
fulfil
marker
diva
vaccin
criteria
see
work
ongo
vector
may
develop
deliv
protect
epitop
antigen
import
diseas
caus
virus
rumin
order
multidiseas
vaccin
also
pertin
note
limit
factor
fmd
viru
r
laboratori
world
abl
work
live
viru
core
laboratori
global
fmd
allianc
gfra
aim
research
design
construct
develop
new
gener
vaccin
pirbright
laboratori
institut
anim
health
uk
joint
us
depart
agricultur
homeland
secur
laboratori
plum
island
new
york
usa
australian
anim
health
laboratori
geelong
nation
centr
foreign
anim
diseas
winnipeg
canada
intern
livestock
research
institut
ilri
nairobi
kenya
rinderpest
cattl
plagu
highli
contagi
infect
cattl
spread
viru
aerosol
typic
caus
fever
eros
mucou
membran
mouth
upper
respiratori
tract
sever
diarrhoea
lead
dehydr
death
case
mortal
caus
viru
rpv
belong
genu
morbilliviru
famili
paramyxovirida
diseas
confin
part
africa
enzoot
area
mass
vaccin
practis
calf
kidney
cell
attenu
live
viru
vaccin
diseas
nearli
erad
vaccin
also
use
protect
sheep
goat
relat
morbilliviru
pest
de
petit
rumin
pprv
convent
vaccin
effect
ongo
work
uk
french
laboratori
develop
test
new
capri
pox
viru
vector
vaccin
aim
control
major
viru
diseas
africa
rpv
one
candid
list
lumpi
skin
diseas
lsd
cattl
caus
strain
capri
poxviru
lsd
viru
lsdv
diseas
characteris
fever
nodul
skin
mucou
membran
intern
organ
subcutan
oedema
enlarg
superfici
lymph
node
sometim
death
abort
enzoot
area
part
africa
live
vaccin
cattl
sheep
goat
origin
use
poxvirus
affect
million
cattl
well
million
sheep
goat
develop
countri
particularli
africa
mention
much
expert
effort
develop
new
capri
pox
viru
vector
multidiseas
vaccin
lsdv
cross
eu
control
measur
would
appli
exot
notifi
infect
fmdv
vesicular
stomat
viru
vsv
caus
acut
viral
diseas
cattl
hors
deer
pig
occasion
human
diseas
cattl
resembl
fmd
pig
lesion
similar
viral
vesicular
diseas
vsv
occur
america
vsv
seen
europ
sinc
first
time
mode
viru
transmiss
fulli
known
mechan
spread
mosquito
sand
fli
contact
spread
consid
like
common
sign
infect
excess
saliv
vesicl
buccal
caviti
hard
palat
lip
gum
tongu
teat
may
lead
mastiti
fever
weight
milk
yield
loss
addit
effect
vsv
infect
cattl
occasion
host
rabi
viru
eu
five
kill
rabi
viru
vaccin
market
recommend
use
along
wildlif
control
mostli
rabi
red
fox
vulp
vulp
use
oral
vaccin
deliv
bait
fishmeal
fat
paraffin
contain
attenu
rabi
viru
replic
recombin
vaccinia
viru
express
rabi
viru
glycoprotein
latter
vaccin
highli
effect
reduc
incid
wildlif
rabi
mainland
europ
rabi
major
diseas
cattl
area
latin
america
vampir
bat
diseas
commonli
known
derriengu
paralyt
rabi
control
bovin
paralyt
rabi
latin
american
countri
sinc
late
focus
vaccin
cattl
measur
reduc
vampir
bat
popul
variabl
success
virus
mani
differ
famili
infect
domest
pig
caus
signific
econom
loss
howev
level
sophist
approach
use
toward
vaccin
develop
quit
variabl
depend
viru
molecular
biolog
use
appli
deriv
candid
live
attenu
subunit
marker
vaccin
viru
diseas
notabl
caus
prv
classic
swine
fever
viru
csfv
case
prv
identif
virulenceassoci
nonessenti
essenti
gene
function
led
develop
effect
safe
convent
well
biotech
delet
mutant
marker
vaccin
interest
find
live
prv
vaccin
superior
protect
given
vaccin
adjuv
routin
prophylact
vaccin
csfv
eu
ceas
still
provis
emerg
vaccin
certain
circumst
asid
howev
oral
vaccin
wild
boar
su
scrofa
scrofa
live
chines
c
strain
csfv
vaccin
conduct
franc
germani
order
improv
herd
immun
probabl
due
reduc
viru
shed
vaccin
boar
abil
discrimin
vaccin
infect
anim
serolog
use
biotech
vaccin
care
assess
outsid
eu
csfv
vaccin
domest
pig
wide
practis
use
live
cstrain
vaccin
well
biotech
csfv
glycoprotein
subunit
marker
vaccin
applic
biotech
techniqu
develop
experiment
commerci
vaccin
includ
use
subunit
marker
vaccin
express
baculo
viru
subunit
vaccin
chimer
bvdvcsfv
marker
vaccin
recombin
prv
express
csfv
glycoprotein
shown
protect
diseas
due
prv
csfv
porcin
reproduct
respiratori
syndrom
prrsv
porcin
epidem
abort
syndrom
pear
due
arteri
viru
relat
eav
econom
import
rel
recent
diseas
domest
pig
first
identifi
usa
canada
diseas
struck
germani
winter
spread
netherland
part
eu
prr
characteris
high
prewean
mortal
high
reproduct
loss
type
vaccin
use
controversi
issu
prrsv
vaccin
manufactur
final
opt
live
attenu
vaccin
deriv
passag
monkey
kidney
cell
kill
vaccin
command
signific
share
market
poorli
protect
remain
clear
need
effect
vaccin
challeng
compound
fact
prrsv
readili
mutat
pig
singl
episod
result
select
perpetu
pathogen
strain
pig
lower
protect
cover
exist
vaccin
cattl
rumin
fmdv
import
caus
diseas
domest
pig
control
eu
similar
cattl
domest
pig
also
host
import
diseas
caus
picornavirus
notabl
swine
vesicular
diseas
viru
svdv
teschen
diseas
viru
tdv
encephalomyocard
viru
ecmv
three
picornavirus
transmit
oropharyng
rout
svdv
notifi
viru
vaccin
allow
eu
although
outbreak
svdv
occur
eu
countri
notabl
netherland
itali
portug
also
earli
svdv
diseas
similar
fmd
viru
antigen
relat
human
coxsaci
viru
tdv
vaccin
avail
infect
rare
diagnos
main
clinic
sign
tdv
infect
coordin
paralysi
sourc
primari
outbreak
svdv
diseas
europ
unknown
rout
svdv
transmiss
frequent
obscur
america
current
free
svdv
african
swine
fever
asf
highli
contagi
fatal
haemorrhag
diseas
domest
pig
caus
larg
doubl
strand
dna
viru
asfv
famili
asfarvirida
eu
notifi
diseas
asfv
enzoot
subsaharan
countri
cross
atlant
ocean
outbreak
record
south
american
countri
caribbean
island
outbreak
asf
occur
europ
iberian
peninsula
sardinia
sporad
franc
belgium
european
foci
asfv
infect
erad
slaughter
polici
infect
pig
shed
viru
excret
live
viru
spread
horizont
vertic
bite
infect
soft
tick
ornithodoru
moubata
porcin
viru
replic
kill
vaccin
fail
protect
diseas
live
vaccin
revert
virul
fail
infect
pig
asfv
subsaharan
africa
exist
wild
cycl
infect
soft
tick
genu
ornithodor
wild
swine
warthog
bush
pig
remain
clinic
normal
viru
epidemiolog
make
erad
difficult
incurs
asfv
europ
continu
georgia
recent
june
offici
report
asf
viru
rapidli
spread
throughout
georgia
high
mortal
pig
popul
outbreak
asf
also
occur
nearbi
armenia
recent
also
russia
report
asf
effect
safe
asfv
vaccin
clearli
requir
indic
possibl
protect
effect
asfv
vaccin
attribut
structur
viru
protein
produc
long
vaccin
viru
propag
anim
andor
pig
macrophag
cultur
gene
protect
antigen
lost
viru
adapt
grow
convent
tissu
cultur
conclud
protect
protein
essenti
viru
replic
tissu
cultur
essenti
vaccin
product
convent
biotech
virusbas
vaccin
may
possibl
construct
recombin
viru
asfv
gene
stabl
configur
first
protect
gene
need
identifi
characteris
histor
two
pathogen
subtyp
swine
influenza
viru
siv
cocircul
domest
pig
eu
america
new
siv
subtyp
recent
emerg
part
eu
kill
siv
vaccin
contain
siv
avail
pig
vaccin
siv
vaccin
fulli
protect
challeng
despit
observ
siv
main
caus
porcin
respiratori
diseas
complex
littl
attent
paid
routin
vaccin
pig
influenza
develop
improv
efficaci
vaccin
regard
experiment
vaccin
recent
emerg
reassort
subtyp
siv
usa
develop
ha
nucleoprotein
np
gene
viru
express
replicationdefect
human
adenoviru
recombin
siv
vaccin
fulli
protect
piglet
control
challeng
studi
porcin
member
genu
circo
viru
famili
circovirida
associ
postwean
multisystem
wast
syndrom
pmw
also
dermat
nephropathi
syndrom
abort
reproduct
failur
pmw
first
record
usa
canada
late
eu
mid
current
compani
market
kill
vaccin
contain
adjuv
vaccin
porcin
kidney
cell
line
grown
two
capsid
protein
express
baculo
viru
chimera
gene
backbon
subunit
capsid
protein
vaccin
sold
usa
eu
latin
america
asian
countri
convent
produc
vaccin
market
authoris
eu
countri
vaccin
demonstr
good
efficaci
us
canada
interestingli
chimera
apathogen
backbon
offer
live
vaccin
reason
may
difficulti
licens
live
gmo
product
eu
dna
clone
chimera
also
protect
challeng
pig
insect
cell
baculo
viru
construct
produc
selfassembl
viruslik
particl
combin
adjuv
induc
immun
respons
piglet
vaccin
approach
investig
fusion
gene
insert
attenu
prv
strain
live
recombin
viru
immunogen
pig
prv
inocul
pig
produc
lymphocyt
neutralis
antibodi
orf
capsid
gene
express
adenoviru
live
recombin
protect
pig
isol
vari
genet
patholog
therefor
current
new
vaccin
broadli
protect
strain
howev
current
vaccin
strain
claim
genet
stabil
recent
new
serotyp
viru
emerg
usa
caus
consider
loss
pig
near
fatten
stage
studi
howev
shown
infect
immun
protect
challeng
vice
versa
experiment
pig
model
main
consequ
porcin
parvoviru
transplacent
infect
earli
pregnanc
caus
resorpt
subsequ
stage
transplacent
infect
result
stillbirth
mummif
embryon
death
key
stage
pathogenesi
viru
ingest
viru
growth
small
intestin
viraemia
secondari
infect
divid
cell
endometrium
follow
transplacent
infect
embryo
foetu
live
kill
vaccin
market
sever
manufactur
parvoviru
vaccin
significantli
prevent
transplacent
transmiss
viru
shown
econom
profit
europ
product
mostli
kill
live
vaccin
gener
avail
usa
bluetongu
viru
btv
genu
orbiviru
famili
reovirida
current
serotyp
member
segment
rna
genom
reassort
vivo
btv
noncontagi
viru
transmit
biolog
approxim
speci
bite
midg
genu
culicoid
endem
area
differ
speci
midg
involv
btv
transmiss
bt
first
describ
south
africa
sinc
recognis
countri
tropic
subtrop
europ
eight
btv
btv
serotyp
appear
northern
europ
rumin
includ
sheep
goat
cattl
buffalo
antelop
deer
camel
suscept
btv
infect
viru
also
caus
sever
diseas
death
whitetail
deer
usa
howev
bt
sheep
signific
clinic
patholog
econom
impact
temper
area
world
infect
anim
tropic
subtrop
countri
common
clinic
diseas
indigen
speci
unusu
infect
via
saliva
bite
midg
viru
undergo
primari
replic
region
lymph
node
viru
carri
blood
leukocyt
target
tissu
secondari
replic
result
patholog
sheep
common
diseas
sign
lesion
fever
hyperaemia
cyanosi
mouth
tongu
diarrhoea
mortal
pregnant
ewe
viru
may
cross
placenta
lead
foetal
infect
caus
abort
mummif
birth
stillborn
weak
lamb
btv
caus
diseas
cattl
current
outbreak
northern
europ
sporad
episod
diseas
death
small
proport
infect
cattl
herd
consist
record
elber
arw
other
cattl
clinic
sign
commonli
observ
crusti
lesion
nasal
mucou
membran
saliv
fever
hyperaemia
apathi
significantli
cattl
import
reservoir
viru
amplifi
host
midg
feed
frequent
cattl
import
develop
btv
epidemiolog
recent
evid
transplacent
contact
transmiss
btv
cattl
lack
signific
crossprotect
serotyp
make
control
bt
vaccin
difficult
task
notwithstand
difficulti
immunoprophylaxi
tri
kill
live
biotech
vaccin
import
drawback
kill
vaccin
requir
high
antigen
mass
dose
rumin
order
elicit
activ
immun
drawback
issu
live
btv
vaccin
howev
potenti
revert
virul
reassort
cross
placenta
may
shed
semen
risk
asid
live
vaccin
use
extens
success
sheep
south
africa
israel
usa
limitedli
mediterranean
basin
ondersteport
biolog
product
ltd
south
africa
major
manufactur
live
btv
vaccin
eu
btv
vaccin
bank
current
outbreak
kill
vaccin
compani
commiss
use
singl
dose
sheep
two
dose
cattl
vaccin
campaign
northern
europ
yield
use
data
futur
newer
biotech
approach
investig
howev
hold
much
promis
btvlike
viru
corelik
structur
construct
use
viru
major
minor
capsid
protein
latter
produc
baculo
viru
multipl
express
vector
viruslik
singl
doubleshel
particl
emulsifi
freund
incomplet
adjuv
montanid
adjuv
highli
immunogen
protect
sheep
approach
look
hope
sinc
baculo
viru
express
vector
differ
btv
serotyp
could
prepar
advanc
store
bank
similar
line
fmdv
serotyp
brought
outbreak
start
poxvirus
sheep
goat
capri
poxvirus
close
relat
viru
isol
tend
host
specif
diseas
sever
sheep
pox
notifi
diseas
eu
preval
africa
asia
middl
east
mediterranean
capri
pox
virus
affect
million
sheep
goat
develop
counti
sheep
pox
viru
spv
highli
contagi
commonli
aerosol
spread
infect
sheep
often
fatal
although
recov
anim
immun
passiv
immun
confer
via
colostrum
varieti
live
vaccin
exist
given
annual
current
vaccin
effect
caus
inject
site
lesion
work
ongo
develop
better
vaccin
aim
new
vaccin
provid
one
vaccin
protect
sheep
goat
pox
prefer
also
major
viru
diseas
rumin
along
longer
durat
immun
vaccin
effect
young
face
matern
antibodi
would
also
step
forward
work
ongo
multival
capripoxrpv
pprv
fmdv
btv
sheep
suscept
fmd
import
host
fmd
epidemiolog
european
compani
offer
kill
vaccin
contain
oil
singl
doubl
emuls
aluminium
salt
plu
saponin
adjuv
sheep
immunis
fmd
endem
area
similar
line
cattl
pig
rabi
vaccin
sheep
indic
area
wildlif
fox
skunk
raccoon
bat
rabi
endem
kill
adjuv
vaccin
avail
loupingil
viru
liv
typic
flaviviru
report
part
british
isl
european
countri
tick
particularli
ixod
ricinu
consid
natur
vector
liv
transmiss
reservoir
host
grous
shrew
sheep
clinic
sign
fever
depress
anorexia
viru
may
invad
central
nervou
system
result
muscular
tremor
incordin
ataxia
characterist
loup
gait
kill
vaccin
avail
one
shown
protect
orf
viru
genu
para
poxviru
consid
caus
signific
econom
loss
sheep
farmer
viru
sever
effect
neonat
lamb
nurs
ewe
live
kill
vaccin
avail
demand
uk
approach
million
dose
use
annual
orf
viru
use
deliv
prv
protect
glycoprotein
vector
protect
pig
prv
diseas
challeng
avian
influenza
ai
complex
infect
bird
caus
virus
influenza
genu
present
haemagglutinin
h
neuraminidas
n
subtyp
recognis
least
theori
combin
differ
h
n
subtyp
possibl
practic
aris
virul
ai
virus
aiv
belong
subtyp
although
virus
highli
pathogen
hpai
aiv
caus
milder
primarili
respiratori
diseas
low
pathogen
ai
lpai
unless
exacerb
infect
environment
condit
sinc
ai
infect
due
two
subtyp
lpai
hpai
aiv
lpai
hpai
caus
diseas
poultri
also
human
spread
across
vast
area
thu
consider
pressur
use
vaccin
part
control
polici
intern
scale
howev
would
major
undertak
sinc
ecolog
particularli
spread
transmiss
aiv
complex
although
rel
good
understand
aspect
aiv
epidemiolog
notwithstand
difficulti
autogen
kill
vaccin
lpai
virus
use
mainli
turkey
part
usa
itali
vaccin
hpai
aiv
activ
discourag
may
interfer
serolog
diagnosi
hpai
infect
howev
emphasi
chang
due
high
rise
hpai
lpai
infect
like
human
influenza
viru
vaccin
aiv
vaccin
grown
chicken
egg
human
influenza
vaccin
process
greatli
aid
use
human
influenza
viru
produc
high
growth
viru
h
n
intern
protein
vaccin
viru
h
n
glycoprotein
reassort
method
kilbourn
revers
genet
match
epidemiolog
field
situat
vaccin
avian
influenza
howev
shown
field
classic
grown
inactiv
vaccin
formul
potent
adjuv
offer
crossprotect
relat
pathogen
strain
eu
virus
oie
list
outbreak
poultri
notifi
also
case
rest
world
follow
major
outbreak
hpai
viru
itali
target
prevent
vaccin
campaign
use
differenti
infect
vaccin
anim
diva
strategi
develop
appli
region
lpai
virus
frequent
occur
involv
vaccin
inactiv
lpai
viru
vaccin
follow
regular
serotyp
vaccin
bird
order
identifi
bird
antibodi
hpai
viru
thu
onset
hpai
diseas
upon
identif
hpai
viru
infect
emerg
erad
via
cull
implement
aiv
vaccin
may
taken
elsewher
usa
current
consid
vaccin
one
option
influenza
manag
india
consid
use
china
use
aiv
vaccin
wide
vaccin
control
aiv
diseas
howev
univers
accept
type
aiv
vaccin
also
vari
egg
grown
inactiv
whole
viru
prepar
adjuv
prospect
biotech
vaccin
investig
hold
promis
sever
investig
ongo
exampl
mexican
hpai
virusfowl
pox
viru
recombin
vaccin
newcastl
viru
express
aiv
avian
speci
import
paramyxovirus
newcastl
diseas
viru
ndv
avian
turkey
rhinotrach
viru
trtv
ndv
worldwid
diseas
gallinac
birdschicken
turkey
guineafowl
pheasant
also
pigeon
ndv
strain
classifi
base
three
test
virul
lentogen
mesogen
velogen
signifi
avirul
moder
highli
virul
isol
respect
vaccin
poultri
almost
univers
use
egg
grown
live
lentogen
ndv
vaccin
given
coars
spray
day
age
drink
water
week
age
lentogen
strain
use
hitchner
ulster
vgga
mesogen
lasota
strain
also
use
live
vaccin
oral
aerosol
live
ndv
immunis
serv
bypass
matern
immun
low
site
immunis
ndv
also
offer
kill
polyval
vaccin
combin
ibv
ibdv
andor
trtv
see
abbrevi
virus
polyval
vaccin
recommend
use
booster
vaccin
week
age
follow
live
vaccin
prime
bird
often
boost
point
lay
everi
month
kill
oil
adjuv
vaccin
mesogen
la
sota
strain
live
vaccin
possibl
modifi
sequenc
viru
hn
glycoprotein
proteas
cleavag
site
revers
genet
conjunct
infecti
c
dna
clone
anti
genom
rna
also
lentogen
ndv
strain
investig
candid
vaccin
vector
poultri
diseas
hpai
virus
infecti
laryngotrach
viru
iltv
infecti
bursal
diseas
viru
ibdv
produc
multidiseas
live
vaccin
mass
vaccin
spray
experiment
ndv
vector
approach
success
studi
ha
hpai
viru
express
lentogen
ndv
vaccin
strain
use
revers
genet
fulli
protect
sprayvaccin
chicken
ndv
hpai
viru
diseas
similarli
produc
lpai
viru
ndv
lentogen
hitchner
vaccin
partial
protect
point
experiment
vaccin
markerdiva
vaccin
preval
europ
usa
poultri
produc
countri
caus
respiratori
diseas
stunt
turkey
lay
turkey
vaccin
kill
adjuv
vaccin
primari
ovo
see
live
viru
vaccin
may
effect
also
candid
multival
turkey
viru
vaccin
instanc
trt
viru
hvt
may
feasibl
use
hvt
see
vector
trtv
immunis
chicken
possibl
turkey
sinc
appar
hvt
protect
marek
diseas
turkey
test
franc
turkey
rhinotrach
viru
trtv
belong
genu
pneumo
viru
famili
paramyxovirida
first
isol
mid
respiratori
diseas
main
consequ
field
viru
readili
attenu
passag
egg
tissu
cultur
live
kill
vaccin
market
variat
vaccin
regim
one
regim
live
trtv
vaccin
use
compris
spray
vaccin
chick
subsequ
booster
vaccin
live
vaccin
howev
commonli
result
respiratori
diseas
sinc
vaccin
viru
known
revert
virul
upon
bird
bird
passag
henc
develop
safer
vaccin
without
loss
efficaci
may
warrant
use
revers
genet
may
help
respect
interest
potenti
use
convent
vaccin
trt
aros
studi
report
isol
avirul
trt
viru
strain
wild
canada
goos
live
inoculum
viru
protect
control
challeng
studi
turkey
biotech
vaccin
trt
viru
f
gene
dna
vaccin
induc
protect
turkey
marek
diseas
viru
mdv
occur
worldwid
infect
chicken
age
caus
viscer
neural
lesion
includ
cell
tumour
death
mdv
strain
vari
consider
virul
strain
bird
show
mark
differ
suscept
viru
spread
aerosol
cellfre
viru
shed
feather
follicl
turkey
herp
viru
hvt
wide
use
heterotyp
live
cellfre
viru
cellassoci
viru
vaccin
broiler
hvt
investig
vaccin
vector
avian
viral
diseas
layer
routin
vaccin
hvt
hvt
see
cvi
see
mdv
vaccin
use
tissu
cultur
attenu
serotyp
cvi
rispen
strain
tissu
cultur
passag
variant
variant
less
effect
cvi
serotyp
strain
tissu
cultur
attenu
serotyp
strain
mdv
also
commonli
use
vaccin
vaccin
perform
ovo
day
incub
day
age
sometim
booster
vaccin
given
develop
immun
may
influenc
viral
matern
antibodi
delay
vaccin
viru
replic
mdv
field
strain
gradual
evolv
pathogen
phenotyp
combin
differ
vaccin
mdv
also
use
often
counter
pathogen
field
mdv
infect
sb
hvt
combin
use
vaccin
broiler
prefer
combin
layer
breeder
cvi
hvt
howev
new
vaccin
need
control
emerg
mdv
pathotyp
gallid
genu
iltoviru
alpha
herpesvirina
commonli
known
iltv
preval
wherev
poultri
kept
spread
aerosol
caus
haemorrhag
tracheiti
bronchiti
high
morbid
result
mortal
convent
attenu
live
viru
vaccin
given
spray
surprisingli
choic
iltv
vaccin
limit
iltv
member
alpha
herpesvirina
approach
avail
new
vaccin
exampl
success
appli
prv
duck
also
known
duck
plagu
duck
viral
enter
transmit
aerosol
present
duck
produc
countri
duckl
viru
pantrop
infect
blood
vessel
endothelium
thu
give
rise
multipl
petechia
gener
particularli
heart
liver
kidney
intestin
caus
high
mortal
live
attenu
chicken
egggrown
vaccin
given
subcutan
sc
duckl
week
age
drawback
vaccin
avail
possibl
due
short
shelf
life
low
demand
avian
infecti
bronchiti
viru
ibv
infect
chicken
age
breed
common
caus
chronic
respiratori
diseas
frequent
dual
infect
mycoplasma
spp
andor
septicaemia
caus
e
coli
ibv
spread
rapidli
aerosol
direct
contact
primarili
replic
respiratori
urogenit
tract
epithelia
respiratori
sign
includ
catarrh
tracheiti
bronchiti
sinus
urogenit
tract
infect
result
nephriti
chick
vaccin
live
egggrown
attenu
viru
strain
massachusett
serotyp
strain
spray
day
old
drink
water
week
old
adult
chicken
revaccin
kill
adjuv
usual
oil
vaccin
given
parenter
virul
live
vaccin
respiratori
rout
extens
use
live
ibv
vaccin
suggest
main
caus
emerg
pathogen
ibv
variant
author
develop
vaccin
use
recombin
fowl
adenoviru
express
ibv
spike
glycoprotein
strategi
avoid
problem
demonstr
potenti
would
involv
precis
epidemiolog
investig
possibl
differ
geograph
locat
serotyp
ibdv
belong
famili
birnavirida
commonli
known
gumboro
diseas
viru
signific
caus
diarrhoea
immunosuppress
mortal
chicken
viru
transmiss
via
infect
food
water
viru
primarili
replic
oropharynx
result
viraemia
infect
bursa
nonpathogen
serotyp
strain
ibdv
turkey
also
occur
determin
pathogen
appear
tropism
bursa
fabriciu
difficulti
control
ibdv
diseas
field
emerg
variant
exist
vaccin
partial
protect
control
ibdv
egg
andor
tissu
cultur
attenu
live
vaccin
given
spray
drink
water
residu
mda
declin
suffici
vaccin
take
lay
hen
boost
kill
oili
vaccin
sc
im
rout
serotyp
ibdv
strain
caus
sub
clinic
infect
chicken
turkey
efficaci
primari
ovo
inocul
experiment
live
ibdv
vaccin
report
recent
next
gener
ibdv
vaccin
like
multival
biotech
vaccin
name
one
vaccin
two
poultri
viru
diseas
chicken
anaemia
viru
cav
belong
genu
gyro
viru
famili
cirovirida
low
morbid
typic
result
atrophi
thymu
spleen
caecal
tonsil
bursa
stem
infect
precursor
bone
marrow
cell
also
result
anaemia
skin
lesion
also
commonli
observ
along
mortal
choic
vaccin
limit
live
tissu
cultur
grown
vaccin
im
sc
applic
market
case
vertic
transmit
infect
due
avian
adeno
viru
egg
drop
syndrom
avian
reoviru
infecti
bursal
diseas
viru
gumboro
diseas
adult
bird
vaccin
order
provid
passiv
protect
chick
via
matern
antibodi
good
prospect
new
improv
veterinari
viru
vaccin
futur
onward
nonrepl
viru
vector
nrvv
develop
two
viru
famili
avipox
adeno
virus
recombin
avipox
vector
shown
afford
protect
rabi
canin
distemp
poultri
virus
includ
hpai
viru
howev
except
case
recombin
canari
vaccin
exampl
adenoviru
nrvv
develop
human
express
fmdv
capsid
proteas
test
pig
ha
np
gene
newli
emerg
reassort
siv
usa
bovin
replic
vector
also
develop
prototyp
viru
vector
vaccinia
bacteria
attenu
mycobacterium
bovi
bacilli
bcg
isol
strain
salmonella
typhi
investig
ndv
use
live
vector
well
instanc
express
ai
maker
vaccin
potenti
use
approach
pursu
includ
gener
chimer
virus
belong
genu
employ
full
length
cdna
clone
use
transcrib
infecti
viru
rna
exchang
protect
gene
vaccin
candid
viru
gene
donor
attenu
viru
approach
appli
posit
strand
rna
virus
bvdvcsfv
wnvyellow
fever
viru
combin
belong
genera
pesti
viru
flaviviru
respect
famili
flavivirida
revers
genet
prove
use
techniqu
neg
strand
rna
virus
without
segment
genom
technolog
prove
help
map
virul
motif
gene
produc
viru
chimera
delet
alter
undesir
motifsbas
sequenc
gene
thu
attenu
viru
identifi
gene
function
rabi
viru
vector
provid
highli
stabl
gene
express
furthermor
propos
use
recombin
rhabdovirus
vaccin
hiv
diseas
genet
vaccin
form
dna
vaccin
introduc
earli
investig
wide
rang
infecti
malign
diseas
contrast
vaccin
employ
recombin
virus
bacteria
genet
vaccin
consist
dna
plasmid
rna
mrna
selfrepl
genet
vaccin
see
taken
cell
translat
protein
vaccin
deliv
needl
inject
commonli
muscl
skin
gene
gun
precipit
onto
inert
particl
usual
gold
bead
deliveri
mucos
surfac
respiratori
tract
gut
also
investig
consider
work
field
identifi
sever
paramet
optim
vaccin
perform
includ
use
strong
viral
promot
enhanc
express
immunodomin
epitop
antigen
form
mini
gene
buri
compon
within
unrel
highli
immunogen
core
sequenc
particularli
full
length
toxic
immunosuppress
antigen
defin
epitop
b
cell
target
sequenc
design
direct
intracellular
traffick
helper
epitop
hepat
b
coreantigen
activ
b
cell
elicit
cell
respons
nonmethyl
palindrom
dna
sequenc
contain
cpgoligodinucleotid
usual
bacteri
dna
activ
innat
immun
respons
via
activ
monocyt
natur
killer
nk
cell
dendrit
cell
b
cell
one
promis
approach
genet
vaccin
develop
use
alpha
virus
sindbi
semliki
forest
veev
other
selfrepl
vaccin
positivestrand
rna
virus
encod
rna
replicas
function
broad
rang
cell
mammalian
avian
reptilian
amphibian
insect
cell
replic
take
place
cytoplasm
limit
vaccin
recommend
use
diseas
due
alpha
virus
risk
recombin
alpha
virus
usual
vaccin
construct
involv
foreign
gene
place
alpha
viru
structur
gene
link
alpha
viru
replicas
strong
heterolog
promot
cytomegaloviru
viru
theoret
copi
produc
singl
cell
within
h
express
encod
antigen
much
total
cell
protein
ovo
embryo
vaccin
grow
trend
commerci
poultri
vaccin
overcom
interfer
due
mda
interest
develop
data
directli
compar
new
old
method
requir
reach
object
conclus
although
method
use
year
ovo
inocul
chicken
embryo
perform
day
incub
amniot
caviti
interestingli
commerci
broiler
flock
usa
receiv
mdv
vaccin
ovo
rout
primari
inocul
live
poultri
vaccin
could
given
ovo
inocul
includ
ndv
ibv
ibdv
adjuv
vaccin
deliveri
import
design
new
kill
vaccin
discuss
detail
us
other
refer
therein
complet
howev
pertin
briefli
consid
new
think
includ
vaccin
deliveri
method
induc
primari
immun
respons
young
face
matern
antibodi
singl
inocul
deliveri
system
provid
sustain
releas
antigen
case
former
mucos
immunis
favouredwherea
latter
variou
approach
possibl
oral
bait
edibl
vaccin
liposom
microparticl
polymer
capsul
singl
shot
acidresist
liposom
vaccin
multipl
compon
becom
feasibl
candid
compon
might
includ
sever
antigen
multipl
adjuv
lipophil
muramyl
dipeptid
deriv
monophosphoryl
lipid
bacteri
toxin
cytokin
interferon
ifn
interleukin
genet
modifi
innocu
bacteri
toxin
cholera
toxin
b
pseudomona
exotoxin
e
coli
heat
stabl
toxin
safe
candid
mucos
adjuv
need
sinc
infect
begin
mucos
site
doitallin
one
liposom
approach
attract
costli
veterinari
vaccin
cost
import
aspect
vaccin
develop
manufactur
import
advanc
design
control
releas
system
antigen
deliveri
vivo
polym
polylacticpolyglycol
ester
nontox
biodegrad
vehicl
slow
releas
antigen
period
sever
month
depend
rel
amount
polym
acidresist
hydrophob
matrix
compris
adjuv
saponin
deriv
antigen
cholesterol
phosphatidyl
cholin
commonli
known
iscom
immunostimul
complex
immunogen
intramuscular
well
oralnas
rout
potent
thelper
cell
th
adjuv
envelop
virus
influenza
viru
fact
iscom
equin
influenza
vaccin
avail
uptod
account
technolog
iscomatrix
better
defin
saponin
fraction
use
antigen
present
particl
avail
context
equin
influenza
vaccin
well
anoth
idea
use
polyest
liquid
form
gel
vivo
inject
case
atrigel
drug
deliveri
system
use
pseudorabi
viru
vaccin
pig
dna
plasmid
vaccin
technolog
refin
improv
deliveri
method
like
develop
conjunct
specif
cytokin
dna
plasmid
preferenti
stimul
andor
immun
much
look
forward
cost
inevit
decid
commerci
feasibl
actual
come
market
latter
larg
dictat
margin
profit
minim
especi
poultri
swine
industri
howev
earli
optim
regard
dna
vaccin
temper
subsequ
observ
mani
case
dna
vaccin
perform
poorli
target
anim
initi
success
seen
mice
howev
except
exampl
fort
dodg
west
nile
viru
vaccin
approv
fda
yet
market
sinc
earli
demonstr
diseas
control
vaccin
jenner
follow
year
later
loui
pasteur
scienc
immunoprophylaxi
import
veterinari
virus
grown
enorm
histor
great
stride
made
major
stimuli
vaccin
manufactur
aros
frenkel
method
bulk
product
fmdv
vaccin
vitro
follow
growth
polioviru
tissu
cultur
tissu
cultur
technolog
instrument
scienc
vaccin
develop
manufactur
notwithstand
fact
major
current
veterinari
viral
vaccin
deriv
still
produc
convent
attenu
andor
inactiv
process
tissu
cultur
genet
engin
techniqu
wide
use
remain
fulfil
promis
offer
improv
widespread
econom
altern
howev
perfect
vaccin
goal
may
never
realis
sinc
virus
constantli
mutat
order
surviv
evad
host
defenc
